Agenerase Oral Solution (Amprenavir Oral Solution) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 23, 2012

Agenerase Oral Solution

HIV and AIDS: Antiretroviral Drugs, Treatments and Medications »

Entry Inhibitors (including Fusion Inhibitors) and CCR5 Co-receptor Antagonist

Entry Inhibitors
Entry inhibitors block HIV entry into CD4+ cells.

Fusion inhibitors
The only drug in this class is T-20, which is administered as a twice daily subcutaneous injection. The most common side effect is redness and pain at the site of injection. Rarely, infection can occur at the injection site. There also are reports of generalized allergic reactions.

CCR5 antagonist
Although there were some early concerns of liver inflammation for drugs in this class, MVC appeared to be well tolerated in clinical trials without any specific toxicities attributable to the drug. However, it is a new drug in a new class and the first to actually target the cell. For these reasons, longer follow-up from clinical trials and those followed in the clinic will be very important for assessing the overall safety of the...

Read the HIV and AIDS: Antiretroviral Drugs, Treatments and Medications article »

« Previous
1
2
3
4
5
6
7
8
9
10
Next »

Agenerase Oral Solution

10 Common Allergy Triggers Slideshow Pictures

Take the Quiz on Allergies

Nasal Allergy Relief Slideshow Pictures

font size

Please Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)

OVERDOSE

There is no known antidote for AGENERASE. It is not known whether amprenavir can be removed by peritoneal dialysis or hemodialysis. If overdosage occurs, the patient should be monitored for evidence of toxicity and standard supportive treatment applied as necessary.

AGENERASE Oral Solution (amprenavir oral solution) contains large amounts of propylene glycol. In the event of overdosage, monitoring and management of acid-base abnormalities is recommended. Propylene glycol can be removed by hemodialysis.

CONTRAINDICATIONS

Because of the potential risk of toxicity from the large amount of the excipient, propylene glycol, AGENERASE Oral Solution (amprenavir oral solution) is contraindicated in infants and children below the age of 4 years, pregna nt women, patients with hepatic or renal failure, and patients treated with disulfiram or metronidazole (see WARNINGS and PRECAUTIONS).

Coadministration of AGENERASE is contraindicated with drugs that are highly dependent on CYP3A4 for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These drugs are listed in Table 6.

Table 6. Drugs That Are Contraindicated With AGENERASE Oral Solution

Drug Class	Drugs Within Class That Are CONTRAINDICATED with AGENERASE
Alcohol-dependence treatment	Disulfiram
Antibiotic	Metronidazole
Ergot derivatives	Dihydroergotamine, ergonovine, ergotamine, methylergonovine
GI motility agent	Cisapride
Neuroleptic	Pimozide
Sedatives/hypnotics	Midazolam, triazolam

If AGENERASE Capsules are coadministered with ritonavir capsules, the antiarrhythmic agents flecainide and propafenone are also contraindicated.

AGENERASEis contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any of the components of this product.

Last reviewed on RxList: 7/18/2008
This monograph has been modified to include the generic and brand name in many instances.